Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,226 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity.
Jess J, Yates B, Dulau-Florea A, Parker K, Inglefield J, Lichtenstein D, Schischlik F, Ongkeko M, Wang Y, Shahani S, Cullinane A, Smith H, Kane E, Little L, Chen D, Fry TJ, Shalabi H, Wang HW, Satpathy A, Lozier J, Shah NN. Jess J, et al. Among authors: parker k. J Immunother Cancer. 2023 Jun;11(6):e005898. doi: 10.1136/jitc-2022-005898. J Immunother Cancer. 2023. PMID: 37295816 Free PMC article.
Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies.
Parker KR, Migliorini D, Perkey E, Yost KE, Bhaduri A, Bagga P, Haris M, Wilson NE, Liu F, Gabunia K, Scholler J, Montine TJ, Bhoj VG, Reddy R, Mohan S, Maillard I, Kriegstein AR, June CH, Chang HY, Posey AD Jr, Satpathy AT. Parker KR, et al. Cell. 2020 Oct 1;183(1):126-142.e17. doi: 10.1016/j.cell.2020.08.022. Epub 2020 Sep 21. Cell. 2020. PMID: 32961131 Free PMC article.
Surface Proteomics Reveals CD72 as a Target for In Vitro-Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL.
Nix MA, Mandal K, Geng H, Paranjape N, Lin YT, Rivera JM, Marcoulis M, White KL, Whitman JD, Bapat SP, Parker KR, Ramirez J, Deucher A, Phojanokong P, Steri V, Fattahi F, Hann BC, Satpathy AT, Manglik A, Stieglitz E, Wiita AP. Nix MA, et al. Among authors: parker kr. Cancer Discov. 2021 Aug;11(8):2032-2049. doi: 10.1158/2159-8290.CD-20-0242. Epub 2021 Mar 16. Cancer Discov. 2021. PMID: 33727310 Free PMC article.
Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling.
Weber EW, Parker KR, Sotillo E, Lynn RC, Anbunathan H, Lattin J, Good Z, Belk JA, Daniel B, Klysz D, Malipatlolla M, Xu P, Bashti M, Heitzeneder S, Labanieh L, Vandris P, Majzner RG, Qi Y, Sandor K, Chen LC, Prabhu S, Gentles AJ, Wandless TJ, Satpathy AT, Chang HY, Mackall CL. Weber EW, et al. Among authors: parker kr. Science. 2021 Apr 2;372(6537):eaba1786. doi: 10.1126/science.aba1786. Science. 2021. PMID: 33795428 Free PMC article.
NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity.
Richards RM, Zhao F, Freitas KA, Parker KR, Xu P, Fan A, Sotillo E, Daugaard M, Oo HZ, Liu J, Hong WJ, Sorensen PH, Chang HY, Satpathy AT, Majzner RG, Majeti R, Mackall CL. Richards RM, et al. Blood Cancer Discov. 2021 Sep 16;2(6):648-665. doi: 10.1158/2643-3230.BCD-20-0208. eCollection 2021 Nov. Blood Cancer Discov. 2021. PMID: 34778803 Free PMC article.
GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity.
Heitzeneder S, Bosse KR, Zhu Z, Zhelev D, Majzner RG, Radosevich MT, Dhingra S, Sotillo E, Buongervino S, Pascual-Pasto G, Garrigan E, Xu P, Huang J, Salzer B, Delaidelli A, Raman S, Cui H, Martinez B, Bornheimer SJ, Sahaf B, Alag A, Fetahu IS, Hasselblatt M, Parker KR, Anbunathan H, Hwang J, Huang M, Sakamoto K, Lacayo NJ, Klysz DD, Theruvath J, Vilches-Moure JG, Satpathy AT, Chang HY, Lehner M, Taschner-Mandl S, Julien JP, Sorensen PH, Dimitrov DS, Maris JM, Mackall CL. Heitzeneder S, et al. Among authors: parker kr. Cancer Cell. 2022 Jan 10;40(1):53-69.e9. doi: 10.1016/j.ccell.2021.12.005. Epub 2021 Dec 30. Cancer Cell. 2022. PMID: 34971569 Free PMC article.
Enhanced safety and efficacy of protease-regulated CAR-T cell receptors.
Labanieh L, Majzner RG, Klysz D, Sotillo E, Fisher CJ, Vilches-Moure JG, Pacheco KZB, Malipatlolla M, Xu P, Hui JH, Murty T, Theruvath J, Mehta N, Yamada-Hunter SA, Weber EW, Heitzeneder S, Parker KR, Satpathy AT, Chang HY, Lin MZ, Cochran JR, Mackall CL. Labanieh L, et al. Cell. 2022 May 12;185(10):1745-1763.e22. doi: 10.1016/j.cell.2022.03.041. Epub 2022 Apr 27. Cell. 2022. PMID: 35483375 Free PMC article.
Engineered cell entry links receptor biology with single-cell genomics.
Yu B, Shi Q, Belk JA, Yost KE, Parker KR, Li R, Liu BB, Huang H, Lingwood D, Greenleaf WJ, Davis MM, Satpathy AT, Chang HY. Yu B, et al. Cell. 2022 Dec 22;185(26):4904-4920.e22. doi: 10.1016/j.cell.2022.11.016. Epub 2022 Dec 13. Cell. 2022. PMID: 36516854 Free PMC article.
Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells.
Tsuchida CA, Brandes N, Bueno R, Trinidad M, Mazumder T, Yu B, Hwang B, Chang C, Liu J, Sun Y, Hopkins CR, Parker KR, Qi Y, Hofman L, Satpathy AT, Stadtmauer EA, Cate JHD, Eyquem J, Fraietta JA, June CH, Chang HY, Ye CJ, Doudna JA. Tsuchida CA, et al. Cell. 2023 Oct 12;186(21):4567-4582.e20. doi: 10.1016/j.cell.2023.08.041. Epub 2023 Oct 3. Cell. 2023. PMID: 37794590 Free PMC article.
2,226 results